FindTrial
Sign In

Tight control for the anti- TNF alpha antibody- treated CD (Crohn's disease) patients with thiopurine intensification determined by the capsule endoscopic appearances of small intestinal rejoins

Tight control for the anti- TNF alpha antibody- treated CD (Crohn's disease) patients with thiopurine intensification determined by the capsule endoscopic appearances of small intestinal rejoins - Tactics study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000013078
Enrollment
50
Registered
2014-03-01
Start date
2014-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

thiopurine derivatives

Sponsors

Saitama Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: anti-TNF alpha antibody treated CD patients without steroids whose CDAI titer is below 150 patients with informed consents

Exclusion criteria

Exclusion criteria: patients refractory with infliximab and adalimumab patients refractory with thiopurine derivatives patients whose WBC titer is under 3000/mm3 pregnant patients patients in the lactation patients has past history of malignancy patients who in not suitable to this study determined by doctors

Design outcomes

Primary

MeasureTime frame
improvement ratio of small intestinal regions evaluated by CECDAI at 6 months—

Secondary

MeasureTime frame
mucosal healing rates of small intestinal regions at 6 months serum CRP titer at 6 months serum anti-TNF alpha concentration at 6 months safety—

Countries

Japan

Contacts

Public ContactShingo kato

Saitama Medical Center Department of gastroenterology and Hepatology

skato@saitama-med.ac.jp049-228-3564

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026